DexCom compounded from near nothing to roughly 165 by late 2021 on the continuous-glucose-monitoring story. It then took two separate hits: a de-rating through 2022 into the low 90s, and a far more damaging single-session guidance reset in mid-2024 that took price from about 140 to the mid-60s.

Since then, nothing much - and that is the interesting part. Price has spent roughly two years grinding sideways between about 58 and 90. Two years of two-way volume in a defined range after a crash is absorption, and it is how post-crash names eventually repair.

The problem is the entry. At 83.02 price sits near the top of that base, and this week it opened at 85.25, printed 87.85, and sold back to 83.02. That is a rejection at range resistance, not a breakout from it.


STRUCTURE I'M WATCHING

All-time high ........ 165 ....... Late 2021. Requires a full growth re-rating.
Resistance 3 ......... 140 – 145 . The 2024 pre-crash level.
Resistance 2 ......... 110 – 115 . First meaningful objective above the base.
Base top / trigger ... 88 – 92 ... The breakout level. Rejected this week.
Current .............. 83.02 ..... Top of the base. Worst risk/reward in the range.
Mid-base ............. 70 – 72 ... Where a pullback becomes interesting.
Base floor ........... 58 – 62 ... The 2026 low. The reference support.
Invalidation ......... below 58 .. Two-year base failure.


WHAT THE CHART IS TELLING ME

- The base is genuine and long. Two years between 58 and 90 means real price memory across the whole range, not a single wick low.
- The balance sheet can wait. A 7 of 9 Piotroski score and moderate leverage mean this is not distressed. Time is not working against the company.
- This week is a rejection. Open near the high, close near the low, at range resistance. Wrong bar to buy.
- The arithmetic at 83 is bad, and worth stating plainly. From 83 with invalidation at 58, risk is roughly 30% for about 35% to the first objective at 112 - barely 1:1. From 66, the same 58 stop is roughly 12% risk for 70% upside. Same thesis, same target, radically different trade. Location is doing almost all the work.

On the projection toward 545: that path is roughly 6.5x from spot and needs both growth re-acceleration and large multiple expansion. Forward estimates imply neither. Pattern overlay, not forecast.


FUNDAMENTAL BACKDROP — HEALTHY COMPANY, DEMANDING PRICE

Piotroski F-score .. 7 / 9 .... Strong. The best signal in this table
Net margin ......... 17.94% ... Solid for a device business
Debt / equity ...... 0.51 ..... Moderate and manageable
ROIC ............... ~22% ..... Good, though partially obscured in the panel — verify
P/E trailing ....... 32.77 .... A growth multiple
P/E forward ........ 32.22 .... Essentially IDENTICAL. Consensus models FLAT earnings
Price / book ....... 11.95 .... Expensive. No asset-value floor at the lows
Dividend ........... None ..... No income support
Market cap ......... 31.3B .... Full price for a business not currently growing earnings

That trailing-versus-forward comparison is the whole fundamental story. When both sit near 32x, the market is pricing neither recovery nor decline - it is pricing stasis, at a multiple that only works if growth returns. The base can be perfect and that arithmetic still caps upside until estimates start moving.


FUTURE PLANS — WHAT THE COMPANY IS ACTUALLY BUILDING

(Framework as of my information; product timelines move fast - verify against the latest filings and releases.)

- Extended-wear sensors. Moving from 10-day to 15-day wear cuts cost of goods per day and improves gross margin, while matching a competitor's wear time. The tension: fewer sensors per patient per year means unit revenue falls unless per-sensor pricing holds.
- OTC / cash-pay biosensors. The over-the-counter product aimed at non-insulin Type 2, prediabetes and general metabolic wellness is the vehicle for the entire long-term bull case. It is also the lowest revenue-per-user product in the portfolio.
- Automated insulin delivery integration. Sensors embedded in closed-loop pump algorithms with partner manufacturers. This is the real moat - once a sensor is designed into an AID system, switching is clinically disruptive rather than merely inconvenient.
- International expansion into markets where CGM reimbursement is broadening.
- Next-generation sensor platform development.

Strategic read: DexCom is deliberately trading revenue-per-user for total users. That is the correct move if the addressable market is as large as claimed, but mechanically it compresses average selling prices before volume grows enough to compensate. Flat forward earnings estimates are, essentially, that trade-off showing up in the model.


COMPETITIVE LANDSCAPE

- Effectively a duopoly. One much larger, diversified competitor holds the bigger global installed base, competes aggressively on price, and fields its own OTC product. Crucially, its diversification lets it fund a price war that DexCom cannot match proportionally out of a single product line.
- A third focused competitor is emerging as a large medtech separates its diabetes division into a standalone entity with its own sensor platform.
- Additional entrants from diagnostics majors are arriving in the category.
- Tail risk: credible non-invasive glucose sensing from a consumer-electronics player would be genuinely disruptive. Low near-term probability, very high impact - worth knowing about, not worth positioning for.

Where DexCom wins: sensor accuracy, AID ecosystem integration, US pharmacy channel presence, clinician trust. Where it is exposed: international volume share, and price competition in precisely the segments it needs for growth. The uncomfortable part of the bull case is that the TAM expansion happens where pricing is weakest and competition is most intense.


MACRO LENS

- Duration and rates. This is long-duration equity - value sits in out-year cash flows. At 32x on flat earnings, the multiple is doing all the work, which makes DXCM unusually rate-sensitive. Falling rates support the multiple; sticky rates cap it regardless of how the base looks.
- Reimbursement policy is the largest single macro lever. Coverage expansion for non-insulin Type 2 populations is worth more to earnings than any individual product launch. General healthcare cost-containment pressure works the other way.
- New consumer-cyclical exposure. This is the underappreciated one. Cash-pay OTC sensors are discretionary consumer spending. A weak consumer hits the TAM-expansion story directly, meaning DXCM now carries a consumer-cyclical component it did not have as a purely reimbursed medtech business.
- Tariffs and manufacturing footprint. Multi-country manufacturing creates component and finished-goods tariff exposure - a live cost variable, not a theoretical one.
- FX. Material international revenue means dollar direction moves reported growth independent of unit demand.

All three lenses converge on the same conclusion the arithmetic reached: the base is sound, but the catalyst is estimate revisions turning up - driven by either reimbursement expansion or OTC volume scaling faster than ASP compression. Until then, the multiple caps the move.


INVALIDATION

A decisive weekly close below 58 breaks a two-year base with no structural reference beneath it. At roughly 12x book there is no valuation floor to catch it either.

Softer warning: repeated failures at 88–92 while the floor gets retested means the base is widening rather than completing.


RISKS WORTH NAMING

- Proven gap risk. Roughly 40% lost in a single session on guidance. Size for gaps, not volatility.
- Pricing and reimbursement pressure. Rebates, payer negotiation and OTC cannibalisation all compress revenue per user.
- A larger, diversified rival able to compete on price indefinitely.
- No valuation support. 32x, no dividend, 12x book - sentiment holds the multiple.
- Flat estimates can become falling estimates. A 32x multiple on declining forecasts gets more expensive as price drops.
- Range risk. Two-year bases can become three-year bases. Capital here has an opportunity cost.


TRADE PLAN

Breakout entry ..... Weekly close above 92 with volume expansion
Value entry ........ 62 – 72 on a hold within the base
Invalidation ....... Weekly close below 58
Target 1 ........... 110 – 115
Target 2 ........... 140 – 145
Geometry ........... Roughly 1:1 from 83. Roughly 5:1 from 66. Wait for the level
Sizing ............. Gap risk is demonstrated. Smaller than the chart alone suggests

No position at 83 into a weekly rejection. The base is worth owning - at the bottom of it, or on confirmation above it.


Not financial advice — my own chart interpretation, shared for discussion. Fundamental figures are read from a data panel and one is partially obscured. Pipeline and competitive details are a framework to verify, not current fact. Do your own research and manage your own risk.